Ramucirumab biosimilar (Henlius)

雷莫芦单抗生物类似药（复宏汉霖）

Report date: 2022/07/19 16:22:54

Base Information

Drug NameRamucirumab biosimilar (Henlius)
Drug Alias NameRamucirumab biosimilar (Shanghai Henlius Biotech)雷莫芦单抗生物类似药（Shanghai Henlius Biotech）莫芦单抗生物仿制药 （Shanghai Henlius Biotech）HLX-12
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Henlius Biotech IncShanghai Henlius Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A